Caregiving Preparedness and Self‐Efficacy Following Alzheimer's Disease Biomarker Disclosure: Findings from Care Partners of Individuals with Cognitive Impairment

This study underscores the importance of biomarker status when designing and implementing support services for care partners following biomarker disclosure. A likely explanation of caregiving preparedness being lower and self-efficacy higher when tau+ was disclosed - but the finding being null for amyloid+ - is that care partners of persons with cognitive impairment likely have experience at managing the emotional toll of caregiving but may not be prepared for thinking about the long-term prospect of caregiving following a disclosed tau+ result, an indicator of dementia severity. As the caregiver's role becomes more complex following information about what potentially to expect in the patient (e.g., disease progression), it is crucial to design and implement tailored support services for care partners following biomarker disclosure.